Study explains why Alzheimer's drug is both safe and effective

Aug 18, 2010

Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe Alzheimer's disease and was, in part, developed by Stuart A. Lipton, M.D., Ph.D., Director of the Del E. Web Center for Neuroscience, Aging and Stem Cell Research at Sanford-Burnham Medical Research Institute (Sanford-Burnham).

Memantine improves symptoms by blocking abnormal activity of glutamate, a chemical that transmits messages between nerve cells. In a study appearing August 18 in The , a team of investigators at Sanford-Burnham led by Dr. Lipton unravel exactly how memantine helps Alzheimer's patients without causing serious side effects.

"While memantine is partially effective in treating Alzheimer's disease, one of its major advantages is how safe and well-tolerated it is clinically," said Dr. Lipton

In treating any disease, one of the most difficult parts of designing a new drug is finding ways to maximize its beneficial effect while minimizing harmful side effects. Memantine is a particularly safe treatment for Alzheimer's disease because it dampens excessive glutamate signaling that occurs away from synapses without blocking glutamate activity at the synapses. This is important because interfering with synaptic glutamate signaling would disrupt normal .

"We showed definitively for the first time that memantine, the drug our group developed for Alzheimer's disease, works in a unique way," Dr. Lipton said. "It inhibits a protein that binds glutamate called the NMDA receptor, but predominantly blocks NMDA receptors that signal molecularly to cause neuronal injury and death. It spares the synaptic receptors that mediate normal communication between in the brain."

This finding helps explain why the drug is so well tolerated by Alzheimer's patients and might provide hints for the development of future therapies targeting the NMDA receptor and similar cellular machinery in other diseases.

As many as 5.3 million Americans are living with Alzheimer's, currently the seventh-leading cause of death in the United States.

Explore further: Know the brain, and its axons, by the clothes they wear

Provided by Sanford-Burnham Medical Research Institute

3.5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

New pathway to Parkinson's and Alzheimer's diseases

Jul 29, 2010

Although their genetic underpinnings differ, Alzheimer's disease, Parkinson's disease and Huntington's disease are all characterized by the untimely death of brain cells. What triggers cell death in the brain? According to ...

Alzheimer's disease linked to mitochondrial damage

Apr 02, 2009

Investigators at Burnham Institute for Medical Research (Burnham) have demonstrated that attacks on the mitochondrial protein Drp1 by the free radical nitric oxide—which causes a chemical reaction called S-nitrosylation—mediates ...

Recommended for you

Know the brain, and its axons, by the clothes they wear

Apr 18, 2014

(Medical Xpress)—It is widely know that the grey matter of the brain is grey because it is dense with cell bodies and capillaries. The white matter is almost entirely composed of lipid-based myelin, but ...

Turning off depression in the brain

Apr 17, 2014

Scientists have traced vulnerability to depression-like behaviors in mice to out-of-balance electrical activity inside neurons of the brain's reward circuit and experimentally reversed it – but there's ...

Rapid whole-brain imaging with single cell resolution

Apr 17, 2014

A major challenge of systems biology is understanding how phenomena at the cellular scale correlate with activity at the organism level. A concerted effort has been made especially in the brain, as scientists are aiming to ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
not rated yet Aug 18, 2010
Who funded this work? This sounds more like an advertisement for the drug than a report on new research.
Shootist
not rated yet Aug 18, 2010
I assume you would rather my tax money fund this sort of thing?

I'm not a jaded as you. I trust corporations to try to make profits. They do so by researching and marketing new products. The sales of new products finances the development of newer products.

When was the last time the government made a new product? When was the last time the government made a profit (or even broke even)?
Governments never create, they only take.

More news stories

Cancer stem cells linked to drug resistance

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

Finnish inventor rethinks design of the axe

(Phys.org) —Finnish inventor Heikki Kärnä is the man behind the Vipukirves Leveraxe, which is a precision tool for splitting firewood. He designed the tool to make the job easier and more efficient, with ...

Making graphene in your kitchen

Graphene has been touted as a wonder material—the world's thinnest substance, but super-strong. Now scientists say it is so easy to make you could produce some in your kitchen.